Shanghai Sunway Biotech
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Chinese biotech specializing in GMP viral vector manufacturing and oncolytic virus therapies for oncology.
OncologyImmunology
Technology Platform
Viral vector manufacturing platform specializing in adenovirus, herpes simplex virus, AAV, and lentivirus production with GMP-compliant facilities for oncolytic virus therapies.
Opportunities
Growth opportunities include expanding contract manufacturing services for China's booming cell and gene therapy sector and developing proprietary oncolytic virus candidates for oncology indications.
Risk Factors
Key risks include intensifying competition in viral vector CDMO space, regulatory challenges for novel oncolytic viruses, and dependence on China's evolving CGT ecosystem.
Competitive Landscape
Competes with other Chinese viral vector CDMOs like Wuxi Biologics' WuXi Advanced Therapies division and GeneQuantum, differentiated by early GMP certification for oncolytic adenovirus production.